%	O
%	O
TITLE	O

Cost	B-Study_Type
-	I-Study_Type
effectiveness	I-Study_Type
analysis	I-Study_Type
of	O
routine	O
pneumococcal	O
vaccination	O
in	O
the	O
UK	B-Study_Location
:	O
a	O
comparison	O
of	O
the	O
PHiD	O
-	O
CV	O
vaccine	O
and	O
the	O
PCV	O
-	O
13	O
vaccine	O
using	O
a	O
Markov	O
model	O
.	O

%	O
%	O
ABSTRACT	O

In	O
2010	O
,	O
the	O
13	O
-	O
valent	O
pneumococcal	O
conjugate	O
vaccine	O
(	O
PCV	O
-	O
13	O
)	O
replaced	O
the	O
7	O
-	O
valent	O
vaccine	O
(	O
introduced	O
in	O
2006	O
)	O
for	O
vaccination	O
against	O
invasive	B-Pneumococcal_Disease_Type
pneumococcal	I-Pneumococcal_Disease_Type
diseases	I-Pneumococcal_Disease_Type
(	O
IPDs	B-Pneumococcal_Disease_Type
)	O
,	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
acute	B-Pneumococcal_Disease_Type
otitis	I-Pneumococcal_Disease_Type
media	I-Pneumococcal_Disease_Type
(	O
AOM	B-Pneumococcal_Disease_Type
)	O
in	O
the	O
UK	B-Study_Location
.	O

Using	O
recent	O
evidence	O
on	O
the	O
impact	O
of	O
PCVs	O
and	O
epidemiological	O
changes	O
in	O
the	O
UK	B-Study_Location
,	O
we	O
performed	O
a	O
cost	B-Study_Type
-	I-Study_Type
effectiveness	I-Study_Type
analysis	I-Study_Type
(	I-Study_Type
CEA	I-Study_Type
)	I-Study_Type
to	O
compare	O
the	O
pneumococcal	O
non	O
-	O
typeable	O
Haemophilus	O
influenzae	O
protein	O
D	O
conjugate	O
vaccine	O
(	O
PHiD	O
-	O
CV	O
)	O
with	O
PCV	O
-	O
13	O
in	O
the	O
ongoing	O
national	O
vaccination	O
programme	O
.	O
CEA	O
was	O
based	O
on	O
a	O
published	O
Markov	O
model	O
.	O

The	O
base	O
-	O
case	O
scenario	O
accounted	O
only	O
for	O
direct	O
medical	O
costs	O
.	O

Work	O
days	O
lost	O
were	O
considered	O
in	O
alternative	O
scenarios	O
.	O
Calculations	O
were	O
based	O
on	O
serotype	O
and	O
disease	O
-	O
specific	O
vaccine	O
efficacies	O
,	O
serotype	O
distributions	O
and	O
UK	O
incidence	O
rates	O
and	O
medical	O
costs	O
.	O
Health	O
benefits	O
and	O
costs	O
related	O
to	O
IPD	B-Pneumococcal_Disease_Type
,	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
AOM	B-Pneumococcal_Disease_Type
were	O
accumulated	O
over	O
the	O
lifetime	O
of	O
a	B-Study_Cohort
UK	I-Study_Cohort
birth	I-Study_Cohort
cohort	I-Study_Cohort
.	O
Vaccination	O
of	O
infants	O
at	O
2	O
,	O
4	O
and	O
12â€…months	O
with	O
PHiD	O
-	O
CV	O
or	O
PCV	O
-	O
13	O
,	O
assuming	O
complete	O
coverage	O
and	O
adherence	O
.	O
The	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
was	O
computed	O
by	O
dividing	O
the	O

difference	O
in	O
costs	O
between	O
the	O
programmes	O
by	O
the	O
difference	O
in	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALY	O
)	O
.	O
Under	O
our	O
model	O
assumptions	O
,	O
both	O
vaccines	O
had	O
a	O
similar	O
impact	O
on	O
IPD	O
and	O
pneumonia	O
,	O
but	O
PHiD	O
-	O
CV	O
generated	O
a	O
greater	O
reduction	O
in	O
AOM	B-Pneumococcal_Disease_Type
cases	O
(	O
161â€…918	O
)	O
,	O
AOM	O
-	O
related	O
general	O
practitioner	O
consultations	O
(	O
31â€…070	O
)	O
and	O
tympanostomy	O
tube	O
placements	O
(	O
2399	O
)	O
.	O

At	O
price	O
parity	O
,	O
PHiD	O
-	O
CV	O
vaccination	O
was	O
dominant	O
over	O
PCV	O
-	O
13	O
,	O
saving	O
734	O
QALYs	O
as	O
well	O
as	O
Â£3	O
.	O
68	O
million	O
to	O
the	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
.	O

At	O
the	O
lower	O
list	O
price	O
of	O
PHiD	O
-	O
CV	O
,	O
the	O
cost	O
-	O
savings	O
would	O
increase	O
to	O
Â£45	O
.	O
77	O
million	O
.	O
This	O
model	O
projected	O
that	O
PHiD	O
-	O
CV	O
would	O
provide	O
both	O
incremental	O
health	O
benefits	O
and	O
cost	O
-	O
savings	O
compared	O
with	O
PCV	O
-	O
13	O
at	O
price	O
parity	O
.	O

Using	O
PHiD	O
-	O
CV	O
could	O
result	O
in	O
substantial	O
budget	O
savings	O
to	O
the	O
NHS	O
.	O

These	O
savings	O
could	O
be	O
used	O
to	O
implement	O
other	O
life	O
-	O
saving	O
interventions	O
.	O

%	O
%	O
MATERIALS	O
AND	O
METHODS	O

Model	O
overview	O

The	O
Markov	O
model	O
described	O
here	O
is	O
conceptually	O
iden	O
-	O
tical	O
to	O
the	O
model	O
published	O
earlier	O
by	O
Knerer	O
et	O
al	O
and	O
is	O
essentially	O
an	O
update	O
of	O
that	O
model	O
.	O

shows	O
the	O
ﬂow	O
diagram	O
of	O
the	O
model	O
.	O

Model	O
input	O
data	O
and	O
assumptions	O
were	O
based	O
on	O
published	O
data	O
where	O
pos	O
-	O
sible	O
,	O
and	O
were	O
validated	O
where	O
appropriate	O
by	O
a	O
panel	O
of	O
independent	O
experts	O
(	O
GSK	O
PHiD	O
-	O
CV	O
Health	O
Economics	O
Advisory	O
Board	O
,	O
Leuven	O
,	O
Belgium	O
,	O
September	O
,	O
2013	O
)	O
.	O

This	O
model	O
was	O
used	O
to	O
estimate	O
the	O
epidemiological	O
and	O
economic	O
impact	O
of	O
a	O
universal	O
infant	O
pneumococ	O
-	O
cal	O
vaccination	O
programme	O
in	O
the	O
UK	O
.	O

The	O
model	O
simu	O
-	O
lated	O
the	O
impact	O
of	O
vaccination	O
on	O
invasive	O
and	O

Figure	O
1	O
Model	O
flow	O
diagram	O
.	O

Rectangles	O
represent	O
mutually	O
exclusive	O
health	O
states	O
.	O

Age	O
-	O
specific	O
incidences	O
are	O
applied	O
monthly	O
to	O
the	O
susceptible	O
population	O
.	O

Circles	O
(	O
sequelae	O
and	O
death	O
)	O
and	O
small	O
arrows	O
(	O
natural	O
death	O
)	O
represent	O
the	O
proportion	O
of	O
the	O
population	O
removed	O
from	O
the	O
model	O
.	O

Costs	O
and	O
benefits	O
are	O
computed	O
monthly	O
and	O
aggregated	O
over	O
the	O
cohort’s	O
lifetime	O
.	O

Non	O
-	O
consulting	O
AOM	O
episodes	O
are	O
accounted	O
for	O
in	O
the	O
quality	O
of	O
life	O
calculation	O
.	O

AOM	O
,	O
acute	O
otitis	O
media	O
;	O
Sp	O
,	O
Streptococcus	O
pneumoniae	O
;	O
TTP	O
,	O
tympanostomy	O
tube	O
placement	O
.	O

2	O
Delgleize	O
E	O
,	O
et	O
al	O
.	O

BMJ	O
Open	O
2016	O
;	O
6	O
:	O
e010776	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
bmjopen	O
-	O
2015	O
-	O
010776	O

non	O
-	O
invasive	O
diseases	O
caused	O
by	O
Sp	O
and	O
NTHi	O
-	O
related	O
infections	O
in	O
a	O
birth	O
cohort	O
.	O

It	O
compared	O
two	O
PCVs	O
,	O
PCV	O
-	O
13	O
(	O
currently	O
available	O
in	O
the	O
UK	O
)	O
and	O
PHiD	O
-	O
CV	O
,	O
each	O
given	O
in	O
a	O
three	O
-	O
dose	O
(	O
2	O
+	O
1	O
)	O
schedule	O
with	O
vaccine	O
doses	O
administered	O
at	O
2	O
,	O
4	O
and	O
13	O
months	O
of	O
life	O
.	O

Individuals	O
in	O
the	O
birth	O
cohort	O
were	O
followed	O
in	O
the	O
model	O
over	O
a	O
lifetime	O
with	O
a	O
cycle	O
time	O
of	O
1	O
month	O
.	O

During	O
each	O
model	O
cycle	O
,	O
the	O
probability	O
of	O
an	O
individ	O
-	O
ual	O
entering	O
a	O
speciﬁc	O
health	O
state	O
was	O
governed	O
by	O
age	O
-	O
speciﬁc	O
incidence	O
rates	O
and	O
applicable	O
vaccine	O
efﬁcacy	O
(	O
VE	O
)	O
levels	O
.	O

These	O
transition	O
probabilities	O
determined	O
hospitalisation	O
rates	O
and	O
frequency	O
of	O
medical	O
visits	O
asso	O
-	O
ciated	O
with	O
the	O
disease	O
conditions	O
considered	O
in	O
the	O
model	O
.	O

Costs	O
and	O
quality	O
-	O
adjusted	O
life	O
-	O
years	O
(	O
QALYs	O
)	O
lost	O
associated	O
with	O
the	O
model	O
outcomes	O
(	O
eg	O
,	O
cases	O
,	O
medical	O
visits	O
,	O
hospitalisations	O
)	O
were	O
accumulated	O
over	O
the	O
cohort’s	O
lifetime	O
.	O

The	O
base	O
-	O
case	O
analysis	O
took	O
the	O
per	O
-	O
spective	O
of	O
the	O
healthcare	O
provider	O
in	O
the	O
UK	O
,	O
the	O
National	O
Health	O
Service	O
(	O
NHS	O
)	O
,	O
and	O
therefore	O
accounted	O
only	O
for	O
direct	O
medical	O
costs	O
.	O

An	O
additional	O
analysis	O
accounting	O
for	O
productivity	O
loss	O
was	O
conducted	O
,	O
providing	O
a	O
broader	O
perspective	O
that	O
may	O
further	O
help	O
inform	O
the	O
decision	O
-	O
making	O
process	O
.	O

Epidemiological	O
data	O

Demography	O

The	O
size	O
of	O
the	O
birth	O
cohort	O
in	O
the	O
UK	B-Study_Location
(	O
n=792	O
616	O
infants	O
;	O
reference	O
year	O
mid	O
-	O
2013	O
)	O
and	O
age	O
-	O
speciﬁc	O
overall	O
monthly	O
mortality	O
rates	O
for	O
the	O
general	O
popula	O
-	O
tion	O
were	O
obtained	O
from	O
the	O
Ofﬁce	O
for	O
National	O
Statistics	O
(	O
ONS	O
;	O
see	O
1	O
)	O
.	O

Invasive	B-Pneumococcal_Disease_Type
pneumococcal	I-Pneumococcal_Disease_Type
diseases	I-Pneumococcal_Disease_Type

This	O
section	O
describes	O
the	O
parameters	O
used	O
for	O
the	O
Sp	B-Pneumococcal_Disease_Type
meningitis	I-Pneumococcal_Disease_Type
and	O
bacteraemia	B-Pneumococcal_Disease_Type
natural	O
histories	O
in	O
ﬁ	O
.	O

In	O
the	O
model	O
,	O
all	O
cases	O
of	O
IPD	B-Pneumococcal_Disease_Type
were	O
assumed	O
to	O
be	O
hospi	O
-	O
talised	O
.	O

Transitions	O
from	O
the	O
susceptible	O
state	O
to	O
Sp	O
men	O
-	O
ingitis	O
and	O
bacteraemia	O
requiring	O
inpatient	O
admission	O
were	O
derived	O
from	O
age	O
-	O
speciﬁc	O
hospital	O
admission	O
data	O
from	O
the	O
Hospital	O
Episode	O
Statistics	O
(	O
HES	O
)	O
database	O
2013–2014	O
,	O
and	O
population	O
age	O
distribution	O
data	O
from	O
the	O
ONS	O
(	O
see	O
In	O
the	O
HES	O
database	O
,	O
the	O
International	O
Classiﬁcation	O
of	O
Disease	O
V	O
.	O
10	O
(	O
ICD	O
-	O
10	O
)	O
codes	O
used	O
for	O
meningitis	O
and	O
bacteraemia	O
are	O
G00	O
.	O
1	O
(	O
pneumococcal	O
meningitis	O
)	O
in	O
the	O
primary	O
diagnosis	O
ﬁelds	O
and	O
A40	O
.	O
3	O
(	O
sepsis	O
due	O
to	O
Sp	O
)	O
in	O
all	O
diagnosis	O

ﬁelds	O
,	O
respectively	O
.	O

All	O
diagnosis	O
ﬁelds	O
were	O
used	O
for	O
bacteraemia	O
as	O
this	O
disease	O
condition	O
occurs	O
frequently	O
as	O
a	O
complication	O
.	O

The	O
pathogen	O
-	O
speciﬁc	O
ICD	O
-	O
10	O
codes	O
applied	O
are	O
in	O
line	O
with	O
the	O
deﬁnitions	O
in	O
studies	O
used	O
for	O
VE	O
estimates	O
(	O
see	O
Vaccine	O
efﬁcacy	O
section	O
)	O
.	O

Following	O
meningitis	B-Pneumococcal_Disease_Type
,	O
children	O
and	O
adults	O
can	O
develop	O
long	O
-	O
term	O
neurological	O
sequelae	O
and	O
hearing	O
impairment	O
.	O

The	O
proportion	O
of	O
children	O
with	O
neurological	O
sequelae	O
(	O
7	O
.	O
0	O
%	O
)	O
and	O
hearing	O
impair	O
-	O
ment	O
(	O
13	O
.	O
3	O
%	O
)	O
were	O
based	O
on	O
Pomeroy	O
et	O
al	O
and	O
a	O
meta	O
-	O
analysis	O
of	O
11	O
studies	O
,	O
respectively	O
.	O

For	O
adults	O
,	O
the	O

proportion	O
of	O
meningitis	B-Pneumococcal_Disease_Type
cases	O
with	O
neurological	O
seque	O
-	O
lae	O
(	O
19	O
.	O
0	O
%	O
)	O
and	O
hearing	O
impairment	O
(	O
25	O
.	O
4	O
%	O
)	O
were	O
based	O
on	O
the	O
weighted	O
average	O
of	O
two	O
studies	O
by	O
Kastenbauer	O
and	O
Pﬁster	O
and	O
Auburtin	O
et	O
al	O
.	O

As	O
data	O
are	O
limited	O
in	O
the	O
UK	B-Study_Location
,	O
we	O
conservatively	O
assumed	O
no	O
long	O
-	O
term	O
sequelae	O
following	O
an	O
episode	O
of	O
bacteraemia	O
.	O

Similarly	O
,	O
cases	O
and	O
deaths	O
due	O
to	O
NTHi	O
ID	O
were	O
not	O
included	O
in	O
the	O
base	O
-	O
case	O
analysis	O
.	O

Case	O
-	O
fatality	O
ratios	O
(	O
CFRs	O
)	O
for	O
Sp	O
meningitis	O
and	O
bacteraemia	O
were	O

extracted	O
from	O
Johnson	O
et	O
al	O
and	O
Melegaro	O
and	O
Edmunds	O
,	O
respectively	O
.	O

For	O
children	O
aged	O
≤4	O
years	O
,	O
CFR	O
data	O
were	O
further	O
updated	O
using	O
Ladhani	O
et	O
al	O
.	O

Pneumonia	B-Pneumococcal_Disease_Type

Inpatient	O
incidence	O
rates	O
of	O
all	B-Pneumococcal_Disease_Type
-	I-Pneumococcal_Disease_Type
cause	I-Pneumococcal_Disease_Type
pneumonia	I-Pneumococcal_Disease_Type
were	O
derived	O
from	O
the	O
HES	O
database	O
using	O
ICD	O
-	O
10	O
codes	O
J13	O
(	O
Sp	O
)	O
,	O
J14	O
(	O
Hi	O
)	O
,	O
J15	O
.	O
9	O
(	O
bacterial	O
pneumonia	O
,	O
unspeciﬁed	O
)	O
and	O
J18	O
.	O
1	O
/	O
8	O
/	O
9	O
(	O
lobar	O
pneumonia	O
or	O
unspeciﬁed	O
(	O
pneu	O
-	O
monia	O
/	O
pathogen	O
)	O
;	O
see	O
1	O
)	O
.	O
The	O
broad	O
set	O
of	O
ICD	O
-	O
10	O
codes	O
considered	O
is	O
in	O
line	O
with	O
efﬁcacy	O
end	O
points	O
reported	O
in	O
published	O
clin	O
-	O
ical	O
trials	O
not	O
discriminating	O
between	O
causative	O
patho	O
-	O
gens	O
(	O
see	O
Vaccine	O
efﬁcacy	O
section	O
)	O
.	O

Age	O
-	O
speciﬁc	O
CFRs	O
for	O
inpatient	O
pneumonia	B-Pneumococcal_Disease_Type
were	O
based	O
on	O
data	O
from	O
Melegaro	O
and	O
Edmunds	O
.	O

Outpatient	O
incidence	O
rates	O
were	O
based	O
on	O
2010	O
data	O
from	O
the	O
Royal	O
College	O
of	O
General	O
Practitioners	O
(	O
RCGP	O
)	O
in	O
England	O
and	O
Wales	O
and	O
no	O
mortality	O
was	O
assumed	O
.	O

Acute	B-Pneumococcal_Disease_Type
otitis	I-Pneumococcal_Disease_Type
media	I-Pneumococcal_Disease_Type

Outpatient	O
incidence	O
rates	O
for	O
AOM	B-Pneumococcal_Disease_Type
episodes	O
(	O
not	O
visits	O
)	O
were	O
taken	O
from	O
the	O
RCGP	O
2011	O
Annual	O
Report	O
(	O
ICD	O
-	O
9	O
codes	O
381	O
.	O
0—acute	O
non	O
-	O
suppurative	O
OM	O
,	O
382	O
.	O
0—acute	O
suppurative	O
OM	O
and	O
382	O
.	O
9—unspeciﬁed	O
OM	O
)	O
.	O

The	O
proportion	O
of	O
AOM	B-Pneumococcal_Disease_Type
cases	O
caused	O
by	O
Sp	O
(	O
35	O
.	O
9	O
%	O
)	O
,	O
NTHi	O
(	O
32	O
.	O
3	O
%	O
)	O
and	O
other	O
causative	O
agents	O
(	O
31	O
.	O
8	O
%	O
)	O
were	O
extracted	O
from	O
the	O
review	O
of	O
Leibovitz	O
et	O
al	O
.	O
AOM	B-Pneumococcal_Disease_Type
cases	O
caused	O
by	O
Sp	O
were	O
further	O
distributed	O
between	O
pneumo	O
-	O
coccal	O
serotypes	O
based	O
on	O
a	O
multinational	O
meta	O
-	O
analysis	O
of	O
nine	O
data	O
sets	O
published	O
by	O
Hausdorff	O
et	O
al	O
.	O
The	O
age	O
-	O
speciﬁc	O
rate	O
of	O
tympanostomy	O
tube	O
placement	O
(	O
TTP	O
)	O
was	O
obtained	O
from	O
the	O
HES	O
database	O
using	O
the	O
proced	O
-	O
ural	O
code	O
D15	O
.	O
1	O
(	O
myringotomy	O
with	O
insertion	O
of	O
ventila	O
-	O
tion	O
tube	O
through	O
the	O

tympanic	O
membrane	O
;	O
see	O
1	O
)	O
.	O

The	O
model	O
accounted	O
for	O
the	O
reduced	O
quality	O
of	O
life	O
of	O
patients	O
with	O
AOM	B-Pneumococcal_Disease_Type
not	O
consulting	O
a	O
GP	O
using	O
an	O
adjustment	O
factor	O
,	O
deﬁned	O
as	O
the	O
ratio	O
of	O
GP	O
consultations	O
from	O
Williamson	O
et	O
al	O
over	O
the	O
total	O
number	O
of	O
AOM	B-Pneumococcal_Disease_Type
cases	O
from	O
Melegaro	O
and	O
Edmunds	O
.	O

Finally	O
,	O
our	O
model	O
assumed	O
no	O
complications	O
,	O
long	O
-	O
term	O
sequelae	O
or	O
deaths	O
related	O
to	O
AOM	B-Pneumococcal_Disease_Type
.	O

Costs	O

All	O
costs	O
were	O
reported	O
in	O
British	O
pounds	O
sterling	O
(	O
£	O
)	O
with	O
2014	O
as	O
the	O
reference	O
year	O
.	O

Costs	O
prior	O
to	O
2014	O
were	O
adjusted	O
on	O
the	O
basis	O
of	O
the	O
UK	B-Study_Location
healthcare	O
service	O
cost	O
index	O
(	O
V	O
.	O
02	O
May	O
2013	O
)	O
.	O

The	O
direct	O
annual	O
costs	O
per	O

Delgleize	O
E	O
,	O
et	O
al	O
.	O

BMJ	O
Open	O
2016	O
;	O
6	O
:	O
e010776	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
bmjopen	O
-	O
2015	O
-	O
010776	O
3	O

acute	O
episode	O
are	O
given	O
in	O
the	O
ﬁ2	O
.	O

NHS	O
reference	O
costs	O
(	O
2013–2014	O
)	O
were	O
used	O
to	O
identify	O
cost	O
components	O
including	O
those	O
dependent	O
on	O
disease	O
conditions	O
:	O
for	O
example	O
,	O
ambu	O
-	O
lance	O
transfer	O
,	O
accident	O
and	O
emergency	O
investigation	O
,	O
intensive	O
care	O
unit	O
stay	O
,	O
CT	O
/	O
MRI	O
scanning	O
or	O
X	O
-	O
ray	O
,	O
ultra	O
-	O
sound	O
,	O
weighted	O
average	O
cost	O
of	O
hospital	O
stay	O
and	O
cost	O
of	O
primary	O
care	O
consultation	O
,	O
using	O
information	O
from	O
Melegaro	O
and	O
Edmunds	O
where	O
applicable	O
.	O

Costs	O
asso	O
-	O
ciated	O
with	O
meningitis	B-Pneumococcal_Disease_Type
consisted	O
of	O
two	O
components	O
,	O
the	O
costs	O
of	O
treating	O
the	O
initial	O
meningitis	B-Pneumococcal_Disease_Type
episode	O
and	O
the	O
follow	O
-	O
up	O
costs	O
associated	O
with	O
long	O
-	O
term	O
sequelae	O
(	O
neurological	O
sequelae	O
and	O
hearing	O
loss	O
)	O
incurred	O
over	O
the	O
remaining	O
lifetime	O
.	O

The	O
incidences	O
of	O
sequelae	O
for	O
bacteraemia	O
,	O
all	O
-	O
cause	O
pneumonia	O
and	O
AOM	B-Pneumococcal_Disease_Type
were	O
con	O
-	O
servatively	O
set	O
to	O
zero	O
in	O
the	O
model	O
.	O

In	O
these	O
instances	O
,	O
disease	O
-	O
related	O
treatment	O
costs	O
were	O
assumed	O
to	O
be	O
incurred	O
within	O
1	O
month	O
with	O
no	O
long	O
-	O
term	O
costs	O
due	O
to	O
sequelae	O
.	O

In	O
the	O
base	O
-	O
case	O
scenario	O
,	O
price	O
parity	O
was	O
assumed	O
for	O
PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13	O
.	O

Total	O
vaccine	O
costs	O
per	O
dose	O
were	O
estimated	O
from	O
the	O
list	O
price	O
,	O
accounting	O
for	O
5	O
%	O
wastage	O
and	O
an	O
administration	O
cost	O
of	O
£7	O
.	O
64	O
per	O
dose	O
.	O

The	O
resultant	O
total	O
vaccine	O
cost	O
per	O
dose	O
was	O
estimated	O
at	O

£48	O
.	O
88	O
based	O
on	O
a	O
0	O
.	O
5	O
mL	O
preﬁlled	O
syringe	O
.	O

Vaccination	O
coverage	O
was	O
assumed	O
to	O
be	O
100	O
%	O
,	O
in	O
line	O
with	O
vaccin	O
-	O
ation	O
rates	O
commonly	O
obtained	O
with	O
national	O
immunisa	O
-	O
tion	O
programmes	O
in	O
the	O
UK	O
.	O
Furthermore	O
,	O
a	O
complete	O
course	O
(	O
three	O
doses	O
)	O
with	O
perfect	O
adherence	O
(	O
100	O
%	O
)	O
was	O
assumed	O
.	O

Although	O
these	O
assumptions	O
on	O
coverage	O
and	O
adherence	O
are	O
simpliﬁed	O
,	O
they	O
affect	O
both	O
vaccines	O
equally	O
and	O
therefore	O
should	O
not	O
have	O
an	O
impact	O
on	O
the	O
cost	O
-	O
effectiveness	O
ratio	O
.	O

Utilities	O

Three	O
types	O
of	O
utility	O
values	O
were	O
used	O
in	O
the	O
model	O
.	O

Normative	O
utility	O
values	O
represent	O
the	O
age	O
-	O
speciﬁc	O
utility	O
in	O
healthy	O
individuals	O
.	O

The	O
QALY	O
loss	O
per	O
episode	O
was	O
computed	O
for	O
acute	O
diseases	O
using	O
the	O
formula	O
(	O
1	O

−QALY	O
weight	O
)	O
×	O
(	O
duration	O
of	O
episode	O
in	O
days	O
/	O
365	O
days	O
)	O
.	O

The	O
QALY	O
loss	O
per	O
year	O
(	O
1−QALY	O
weight	O
)	O
was	O
used	O
for	O
long	O
-	O
term	O
conditions	O
(	O
see	O
3	O
)	O
.	O

In	O
the	O
literature	O
,	O
studies	O
looking	O
at	O
long	O
-	O
term	O
meningitis	O
sequelae	O
have	O
variable	O
follow	O
-	O
up	O
times	O
(	O
5–20	O
years	O
)	O
.	O
In	O
our	O
model	O
and	O
others	O
,	O
disutility	O
weights	O
for	O
long	O
-	O
term	O
sequelae	O
were	O
incurred	O
for	O
the	O
time	O
remaining	O
until	O
the	O
end	O
of	O
the	O
study	O
time	O
horizon	O
.	O

Vaccine	O
efficacy	O

In	O
the	O
base	O
-	O
case	O
analysis	O
,	O
the	O
impact	O
of	O
vaccination	O
was	O
assessed	O
including	O
both	O
direct	O
and	O
indirect	O
effects	O
of	O
protection	O
(	O
herd	O
protection	O
)	O
.	O

To	O
estimate	O
the	O
direct	O
effect	O
of	O
vaccination	O
,	O
published	O
estimates	O
of	O
VE	O
were	O
applied	O
to	O
the	O
age	O
-	O
speciﬁc	O
disease	O
incidence	O
in	O
sequen	O
-	O
tial	O
model	O
cycles	O
.	O

The	O
VE	O
estimates	O
used	O
in	O
the	O
model	O
and	O
described	O
in	O
this	O
section	O
have	O
been	O
validated	O
by	O
a	O
panel	O
of	O
independent	O
experts	O
(	O
GSK	O
PHiD	O
-	O
CV	O
Health	O

Economics	O
Advisory	O
Board	O
,	O
Leuven	O
,	O
Belgium	O
,	O
September	O
,	O
2013	O
;	O
)	O
.	O

Invasive	B-Pneumococcal_Disease_Type
pneumococcal	I-Pneumococcal_Disease_Type
diseases	I-Pneumococcal_Disease_Type

Overall	O
efﬁcacy	O
against	O
meningitis	B-Pneumococcal_Disease_Type
and	O
bacteraemia	B-Pneumococcal_Disease_Type
was	O
computed	O
for	O
both	O
vaccines	O
based	O
on	O
the	O
serotype	O
-	O
speciﬁc	O
efﬁcacy	O
estimates	O
from	O
Whitney	O
et	O
aland	O
the	O
local	O
sero	O
-	O
type	O
distribution	O
derived	O
from	O
Waight	O
et	O
al	O
(	O
see	O
ﬁ1	O
)	O
.	O
The	O
efﬁcacy	O
used	O
for	O
all	O
vaccine	O
serotypes	O
included	O
in	O
PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13	O
was	O
the	O
average	O
efﬁcacy	O
reported	O
by	O
Whitney	O
et	O
al	O
against	O
PCV	O
-	O
7	O
serotypes	O
(	O
serotype	O
-	O
speciﬁc	O
efﬁcacy	O
estimates	O
were	O
not	O
used	O
as	O
for	O
some	O
serotypes	O
the	O
number	O
of	O
cases	O
was	O
too	O
small	O
)	O
,	O
except	O
for	O
serotype	O
3	O
.	O

Serotype	O
3	O
is	O
included	O
in	O
PCV	O
-	O
13	O
but	O
not	O
in	O
PHiD	O
-	O
CV	O
.	O

However	O
,	O
both	O
PCV	O
-	O
13	O
and	O
a	O
precursor	O
of	O
PHiD	O
-	O
CV	O
have	O
failed	O
to	O
show	O
signiﬁcant	O
efﬁ	O
-	O
cacy	O
against	O
serotype	O
3	O
,	O
probably	O
because	O
of	O
its	O
thicker	O
polysaccharide	O
capsule	O
.	O

In	O
addition	O
to	O
efﬁcacy	O
against	O
vaccine	O
serotypes	O
,	O
large	O
PCV	O
clinical	O
trials	O
have	O
shown	O
that	O
serotypes	O
19F	O
and	O
6B	O
can	O
also	O
induce	O
protection	O
against	O
19A	O
and	O
6A	O
,	O
respect	O
-	O
ively	O
,	O
because	O
they	O
functionally	O
belong	O
to	O
the	O
same	O
ser	O
-	O
ogroup	O
.	O

Cross	O
-	O
protection	O
against	O
serotype	O
6A	O
(	O
76	O
%	O
)	O
owing	O
to	O
serotype	O
6B	O
(	O
included	O
in	O
all	O
PCVs	O
)	O
has	O
been	O
demonstrated	O
in	O
PCV	O
-	O
7	O
trials	O
.	O

Finally	O
,	O
large	O
clinical	O
trials	O
in	O
Brazil	O
,	O
Canada	O
and	O
Finland	O
have	O
reported	O
VE	O
against	O
19A	O
in	O
IPD	O
of	O
82	O
%	O
,	O
71	O
%	O
and	O
62	O
%	O
,	O
respectively	O
,	O
which	O
prompted	O
an	O
update	O
of	O
the	O
Summary	O
of	O
Product	O
Characteristics	O
(	O
SmPC	O
)	O
for	O
PHiD	O
-	O
CV	O
to	O
include	O
protection	O
against	O
19A	O
(	O
the	O
European	O
Medicines	O
Agency	O
(	O
EMA	O
)	O
approval	O
on	O
23	O
July	O
2015	O
)	O
.	O
In	O
this	O
analysis	O
,	O
we	O
used	O
the	O
Finnish	O
estimate	O
for	O
VE	O
(	O
62	O
%	O
)	O
because	O
it	O
is	O
based	O
on	O
a	O
2	O
+	O
1	O
PHiD	O
-	O
CV	O
vac	O
-	O
cination	O
schedule	O
administered	O
in	O
a	O
European	O
setting	O
.	O

Pneumonia	B-Pneumococcal_Disease_Type

VE	O
of	O
PCVs	O
against	O
CAP	O
has	O
been	O
assessed	O
in	O
several	O
large	O
-	O
scale	O
,	O
randomised	O
,	O
controlled	O
trials	O
conducted	O
in	O
different	O
settings	O
.	O

These	O
trials	O
have	O
shown	O
that	O
protection	O
against	O
disease	O
is	O
not	O
associated	O
with	O
the	O
number	O
of	O
serotypes	O
included	O
in	O
the	O
vaccine	O
formula	O
-	O
tion	O
.	O

Hence	O
,	O
the	O
model	O
assumed	O
an	O
efﬁcacy	O
of	O
23	O
.	O
4	O
%	O
against	O
X	O
-	O
ray	O
-	O
conﬁrmed	O
consolidated	O
CAP	B-Pneumococcal_Disease_Type
(	O
which	O
usually	O
requires	O
hospitalisation	O
)	O
and	O
7	O
.	O
3	O
%	O
against	O
clinic	O
-	O
ally	O
suspected	O
CAP	O
(	O
commonly	O
managed	O
on	O
an	O
out	O
-	O
patient	O
basis	O
)	O
for	O
both	O
vaccines	O
,	O
based	O
on	O
a	O
clinical	O
trial	O
of	O
PHiD	O
-	O
CV	O
.	O

These	O
estimates	O
are	O
conservative	O
,	O
as	O
post	O
-	O
marketing	O
surveillance	O
data	O
from	O
Brazil	O
have	O
shown	O
a	O
reduction	O
of	O
40	O
%	O
and	O
30	O
%	O
in	O
pneumonia	O
hospitalisa	O
-	O
tions	O
with	O
PHiD	O
-	O
CVand	O
PCV	O
-	O
13	O
,	O
respectively	O
.	O

Acute	B-Pneumococcal_Disease_Type
otitis	I-Pneumococcal_Disease_Type
media	I-Pneumococcal_Disease_Type

VE	O
against	O
all	O
vaccine	O
types	O
except	O
serotype	O
3	O
(	O
same	O
as	O
for	O
IPD	O
)	O
was	O
assumed	O
to	O
be	O
69	O
.	O
9	O
%	O
for	O
both	O
vaccines	O
.	O

VE	O
against	O
non	O
-	O
vaccine	O
types	O
was	O
assumed	O
to	O
be	O
−33	O
.	O
0	O
%	O
for	O
both	O
vaccines	O
to	O
account	O
for	O
serotype	O
replacement	O
.	O

PHiD	O
-	O
CV	O
cross	O
-	O
protection	O
against	O
serotype	O
6A	O
(	O
63	O
.	O
7	O
%	O
)	O
was	O
based	O
on	O
Prymula	O
et	O
aland	O
the	O
cross	O
-	O
protection	O

4	O
Delgleize	O
E	O
,	O
et	O
al	O
.	O

BMJ	O
Open	O
2016	O
;	O
6	O
:	O
e010776	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
bmjopen	O
-	O
2015	O
-	O
010776	O

Table	O
1	O
Model	O
input	O
data	O
:	O
VE	O

IPD	O

VE	O
*	O
%	O
(	O
95	O
%	O
CI	O
)	O

PHiD	O
-	O
CV	O
PCV	O
-	O
13	O
Reference	O
/	O
assumption	O

Ten	O
common	O
serotypes	O
for	O
PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13†	O
94	O
.	O
7‡	O

(	O
87	O
.	O
0	O
to100	O
.	O
0	O
)	O

94	O
.	O
7‡	O

(	O
87	O
.	O
0	O
to100	O
.	O
0	O
)	O

Whitney	O
et	O
al	O

Serotype	O
3	O
0	O
.	O
0	O
0	O
.	O
0	O

(	O
26	O
%	O
in	O
SA	O
)	O

Andrews	O
et	O
al	O

Serotype	O
6A	O
76	O
.	O
0	O

(	O
39	O
.	O
0	O
to	O
90	O
.	O
0	O
)	O

Serotype	O
19A	O
62	O
.	O
0	O

(	O
20	O
to	O
85	O
)	O

94	O
.	O
7	O

(	O
87	O
.	O
0	O
to	O
100	O
.	O
0	O
)	O

94	O
.	O
7	O

(	O
87	O
.	O
0	O
to	O
100	O
.	O
0	O
)	O

Vesikari	O
et	O
al	O
Whitney	O
et	O
al	O
Whitney	O
et	O
al	O
Jokinen	O
et	O
al	O

Pneumonia	O

Per	O
cent	O
of	O
reduction	O
in	O
hospitalisations	O
23	O
.	O
4	O

(	O
8	O
.	O
8	O
to	O
35	O
.	O
7	O
)	O

Per	O
cent	O
of	O
reduction	O
in	O
GP	O
visits	O
7	O
.	O
3	O

(	O
2	O
.	O
1	O
to	O
12	O
.	O
3	O
)	O

23	O
.	O
4	O

(	O
8	O
.	O
8	O
to	O
35	O
.	O
7	O
)	O

7	O
.	O
3	O

(	O
2	O
.	O
1	O
to	O
12	O
.	O
3	O
)	O

Tregnaghi	O
et	O
al	O

AOM	O
without	O
TTP	O

Ten	O
common	O
serotypes	O
for	O
PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13	O
69	O
.	O
9	O

(	O
29	O
.	O
8	O
to	O
87	O
.	O
1	O
)	O

Non	O
-	O
vaccine	O
type	O
Streptococcus	O
pneumoniae	O
−33	O
.	O
0	O

(	O
−33	O
.	O
0	O
to	O
15	O
.	O
0	O
)	O

69	O
.	O
9	O

(	O
29	O
.	O
8	O
to	O
87	O
.	O
1	O
)	O

−33	O
.	O
0	O

(	O
−33	O
.	O
0	O
to	O
15	O
.	O
0	O
)	O

Tregnaghi	O
et	O
al	O

Eskola	O
et	O
al	O

Serotype	O
3	O
0	O
.	O
0	O
0	O
.	O
0	O
As	O
for	O
IPD	O

Serotype	O
6A	O
63	O
.	O
7	O

(	O
−13	O
.	O
9	O
to	O
88	O
.	O
4	O
)	O

69	O
.	O
9	O

(	O
29	O
.	O
8	O
to	O
87	O
.	O
1	O
)	O

Prymula	O
et	O
al	O

Tregnaghi	O
et	O
al	O

Serotype	O
6C	O
0	O
.	O
0	O
63	O
.	O
7	O

(	O
−13	O
.	O
9	O
to	O
88	O
.	O
4	O
)	O

Same	O
as	O
6A	O
for	O
PHiD	O
-	O
CV	O

Serotype	O
19A	O
45	O
.	O
8§	O

(	O
−33	O
to	O
15	O
)	O

69	O
.	O
9	O

(	O
29	O
.	O
8	O
to	O
87	O
.	O
1	O
)	O

Tregnaghi	O
et	O
al	O

*	O
All	O
VE	O
estimates	O
have	O
been	O
validated	O
by	O
an	O
expert	O
panel	O
.	O

†Included	O
serotypes	O
were	O
1	O
,	O
4	O
,	O
5	O
,	O
6B	O
,	O
7F	O
,	O
9V	O
,	O
14	O
,	O
18C	O
,	O
19F	O
and	O
23F	O
.	O

‡PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13	O
were	O
assumed	O
to	O
have	O
the	O
same	O
serotype	O
efficacy	O
for	O
the	O
10	O
common	O
serotypes	O
as	O
the	O
average	O
VE	O
of	O
PCV	O
-	O
7	O
vaccine	O
serotypes	O
(	O
94	O
.	O
7	O
%	O
)	O
.	O

§PHiD	O
-	O
CV	O
efficacy	O
was	O
estimated	O
taking	O
the	O
efficacy	O
ratio	O
of	O
the	O
vaccines	O
in	O
IPD	O
(	O
vaccine	O
serotypes	O
)	O
.	O

¶Extrapolated	O
VE	O
estimates	O
were	O
well	O
in	O
agreement	O
with	O
findings	O
of	O
the	O
FinIP	O
study	O
;	O
the	O
boundaries	O
reflect	O
95	O
%	O
CIs	O
that	O
were	O
used	O
in	O
the	O
sensitivity	O
analyses	O
.	O

AOM	O
,	O
acute	O
otitis	O
media	O
;	O
FinIP	O
,	O
Finnish	O
Invasive	O
pneumococcal	O
disease	O
;	O
GP	O
,	O
general	O
practitioner	O
;	O
IPD	O
,	O
invasive	O
pneumococcal	O
disease	O
;	O
JCVI	O
,	O

Joint	O
Committee	O
on	O
Vaccination	O
and	O
Immunisation	O
;	O
PCV	O
-	O
13	O
,	O
13	O
-	O
valent	O
pneumococcal	O
conjugate	O
vaccine	O
;	O
PHiD	O
-	O
CV	O
,	O
10	O
-	O
valent	O
pneumococcal	O
non	O
-	O
typeable	O
Haemophilus	O
influenzae	O
protein	O
D	O
conjugate	O
vaccine	O
;	O
SA	O
,	O
sensitivity	O
analysis	O
;	O
Sp	O
,	O
Streptococcus	O
pneumoniae	O
;	O
TTP	O
,	O
tympanostomy	O
tube	O
placement	O
;	O
VE	O
,	O
vaccine	O
efficacy	O
.	O

against	O
19A	O
(	O
45	O
.	O
7	O
%	O
)	O
was	O
computed	O
using	O
the	O
ratio	O
of	O
efﬁcacy	O
estimates	O
between	O
PHiD	O
-	O
CV	O
and	O
PCV	O
-	O
13	O
in	O
con	O
-	O
junction	O
for	O
IPD	O
.	O

VE	O
against	O
NTHi	O
-	O
related	O
AOM	B-Pneumococcal_Disease_Type
was	O
assumed	O
to	O
be	O
21	O
.	O
5	O
%	O
for	O
PHiD	O
-	O
CV	O
.	O
0	O
2	O
For	O
PCV	O
-	O
13	O
,	O
the	O
VE	O
was	O
−11	O
.	O
0	O
%	O
,	O
as	O
reported	O
for	O
its	O
predecessor	O
PCV	O
-	O
7	O
.	O
These	O
efﬁcacy	O
estimates	O
,	O
in	O
line	O
with	O
expert	O
val	O
-	O
idation	O
and	O
with	O
data	O
reported	O
by	O
Tregnaghi	O
et	O
al	O
,	O
were	O
applied	O
to	O
the	O
respective	O
serotypes	O
,	O
taking	O
into	O
account	O
the	O
frequency	O
of	O
these	O
serotypes	O
in	O
causing	O
AOM	B-Pneumococcal_Disease_Type
(	O
see	O
1	O
)	O
.	O
A	O
similar	O
approach	O
was	O
used	O
for	O
NTHi	O
-	O
related	O
AOM	B-Pneumococcal_Disease_Type
.	O

VE	O
for	O
both	O
vaccines	O
against	O
AOM	O
with	O
TTP	O
procedures	O
was	O
extrapo	O
-	O
lated	O
using	O
an	O
exponential	O
function	O
based	O
on	O
the	O
results	O
of	O
PCV	O
-	O
7	O
clinical	O
trials	O
and	O
the	O
relative	O
ratio	O
of	O

overall	O
AOM	B-Pneumococcal_Disease_Type
VE	O
.	O

These	O
VE	O
estimates	O
were	O
in	O
agree	O
-	O
ment	O
with	O
the	O
ﬁndings	O
of	O
the	O
Finnish	O
Invasive	O
pneumo	O
-	O
coccal	O
disease	O
(	O
FinIP	O
)	O
study	O
.	O

The	O
higher	O
efﬁcacy	O
of	O
PHiD	O
-	O
CV	O
compared	O
with	O
PCV	O
-	O
13	O
for	O
AOM	O
is	O
reﬂected	O
in	O
the	O
estimates	O
of	O
VE	O
against	O
TTP	O
procedures	O
(	O
)	O
.	O

Direct	O
vaccine	O
protection	O
in	O
children	O
against	O
IPD	B-Pneumococcal_Disease_Type
,	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
AOM	B-Pneumococcal_Disease_Type
is	O
age	O
-	O
speciﬁc	O
.	O

First	O
,	O
during	O
the	O
ramp	O
-	O
up	O
phase	O
VE	O
increases	O
to	O
50	O
%	O
,	O
90	O
%	O
and	O
100	O
%	O
of	O
the	O
type	O
-	O
speciﬁc	O
and	O
disease	O
-	O
speciﬁc	O
VE	O
estimates	O
described	O
above	O
following	O
the	O
ﬁrst	O
,	O
second	O
and	O
booster	O
doses	O
,	O
respectively	O
.	O

Second	O
,	O
from	O
13	O
months	O
(	O
booster	O
dose	O
)	O
to	O
3	O
years	O
of	O
age	O
we	O
assumed	O
that	O
VE	O
does	O
not	O
wane	O
.	O
Finally	O
,	O
VE	O
was	O
assumed	O
to	O
wane	O
expo	O
-	O
nentially	O
from	O
3	O
to	O
10	O
years	O
of	O
age	O
,	O
after	O
which	O
the	O

Delgleize	O
E	O
,	O
et	O
al	O
.	O

BMJ	O
Open	O
2016	O
;	O
6	O
:	O
e010776	O
.	O

doi	O
:	O
10	O
.	O
1136	O
/	O
bmjopen	O
-	O
2015	O
-	O
010776	O
5	O

vaccine	O
stops	O
providing	O
any	O
direct	O
protection	O
to	O
the	O
vac	O
-	O
cinated	O
birth	O
cohort	O
.	O
These	O
assumptions	O
are	O
conserva	O
-	O
tive	O
,	O
since	O
data	O
are	O
now	O
available	O
showing	O
that	O
efﬁcacy	O
does	O
not	O
decrease	O
exponentially	O
after	O
3	O
years	O
.	O

Indirect	O
or	O
herd	O
protection	O
resulting	O
from	O
continual	O
vac	O
-	O
cination	O
of	O
sequential	O
birth	O
cohorts	O
was	O
taken	O
into	O
account	O
for	O
the	O
entire	O
population	O
for	O
IPD	B-Pneumococcal_Disease_Type
only	O
(	O
we	O
conservatively	O
assumed	O
no	O
herd	O
protection	O
for	O
pneumonia	B-Pneumococcal_Disease_Type
and	O
AOM	B-Pneumococcal_Disease_Type
)	O
.	O

Serotype	O
replacement	O
offsets	O
the	O
incremental	O
effect	O
of	O
indirect	O
protection	O
.	O

In	O
the	O
model	O
,	O
indirect	O
protection	O
adjusted	O
for	O
the	O
opposing	O
impact	O
of	O
serotype	O
replacement	O
was	O
applied	O
as	O
a	O
ﬁxed	O
effect	O
to	O
the	O
residual	O
disease	O
inci	O
-	O
dence	O
.	O

This	O
net	O
indirect	O
effect	O
was	O
estimated	O
at	O
30	O
%	O
,	O
removing	O
the	O
necessity	O
to	O
account	O
separately	O
for	O
the	O
effect	O
of	O
serotype	O
replacement	O
.	O
All	O
efﬁcacy	O
estimates	O
and	O
the	O
net	O
indirect	O
effect	O
applied	O
in	O
the	O
model	O
are	O
in	O
line	O
with	O
Tregnaghi	O
et	O
aland	O
were	O
validated	O
by	O
a	O
panel	O
of	O
experts	O
(	O
GSK	O
PHiD	O
-	O
CV	O
Health	O
Economics	O
Advisory	O
Board	O
,	O
Leuven	O
,	O
Belgium	O
,	O
September	O
,	O
2013	O
)	O
.	O

Assumptions	O
regard	O
-	O
ing	O
net	O
herd	O
protection	O
were	O
varied	O
in	O
scenario	O
analyses	O
(	O
15	O
%	O
and	O
0	O
%	O
)	O
,	O
as	O
recent	O
data	O
from	O
the	O
UK	O
suggest	O
high	O
levels	O
of	O
serotype	O
replacement	O
in	O
adults	O
.	O

Cost	O
-	O
effectiveness	O
and	O
sensitivity	O
analysis	O

Health	O
beneﬁts	O
and	O
costs	O
were	O
accumulated	O
over	O
the	O
cohort’s	O
lifetime	O
and	O
discounted	O
at	O
a	O
rate	O
of	O
3	O
.	O
5	O
%	O
to	O
esti	O
-	O
mate	O
the	O
incremental	O
cost	O
-	O
effectiveness	O
ratio	O
(	O
ICER	O
)	O
.	O

The	O
ICER	O
of	O
PHiD	O
-	O
CV	O
compared	O
with	O
PCV	O
-	O
13	O
(	O
expressed	O
in	O
£	O
/	O
QALY	O
)	O
was	O
computed	O
by	O
dividing	O
the	O
difference	O
in	O
costs	O
between	O
the	O
two	O
vaccines	O
by	O
the	O
dif	O
-	O
ference	O
in	O
health	O
outcomes	O
.	O

Sensitivity	O
analyses	O
were	O
performed	O
to	O
capture	O
the	O
effects	O
of	O
parameter	O
uncertainty	O
on	O
model	O
predictions	O
and	O
identify	O
the	O
most	O
inﬂuential	O
parameters	O
.	O

One	O
-	O
way	O
sensitivity	O
analyses	O
were	O
performed	O
by	O
varying	O
each	O
par	O
-	O
ameter	O
one	O
by	O
one	O
within	O
a	O
range	O
of	O
plausible	O
estimates	O
and	O
ranking	O
the	O
parameters	O
based	O
on	O
their	O
impact	O
on	O
the	O
results	O
.	O

In	O
addition	O
,	O
a	O
probabilistic	O
sensitivity	O
analysis	O
(	O
PSA	O
)	O
was	O
performed	O
by	O
simultaneously	O
varying	O
all	O
para	O
-	O
meters	O
to	O
capture	O
their	O
conjoint	O
uncertainty	O
(	O
500	O
differ	O
-	O
ent	O
parameter	O
sets	O
sampled	O
from	O
probability	O
distributions	O
)	O
.	O

Results	O
from	O
the	O
PSA	O
were	O
plotted	O
in	O
a	O
cost	O
-	O
effectiveness	O
plane	O
(	O
QALYs	O
vs	O
costs	O
)	O
,	O
along	O
with	O
the	O
base	O
-	O
case	O
ICER	O
estimate	O
.	O

Ranges	O
used	O
in	O
the	O
one	O
-	O
way	O
sensitivity	O
analyses	O
and	O
the	O
probability	O
distributions	O
used	O
in	O
the	O
PSA	O
are	O
provided	O
in	O
the	O
4	O
.	O

In	O
addition	O
to	O
sensitivity	O
analyses	O
,	O
we	O
performed	O
scen	O
-	O
ario	O
analyses	O
on	O
speciﬁc	O
model	O
assumptions	O
to	O
better	O
understand	O
their	O
impact	O
on	O
the	O
results	O
.	O

Alternative	O
scen	O
-	O
arios	O
explored	O
were	O
as	O
follows	O
:	O
(	O
1	O
)	O
net	O
herd	O
protection	O
reduced	O
to	O
15	O
%	O
and	O
0	O
%	O
to	O
explore	O
the	O
impact	O
of	O
the	O
increased	O
serotype	O
replacement	O
observed	O
in	O
recent	O
years	O
in	O
adults	O
in	O
the	O
UK	O
.	O
(	O
2	O
)	O
Efﬁcacy	O
against	O
serotype	O

3	O
increased	O
to	O
26	O
%	O
for	O
PCV	O
-	O
13	O
(	O
non	O
-	O
signiﬁcant	O
result	O
from	O
)	O
.	O

(	O
3	O
)	O
NTHi	O
ID	O
(	O
meningitis	B-Pneumococcal_Disease_Type
and	O
bacteraemia	B-Pneumococcal_Disease_Type
)	O
and	O
NTHi	O
pneumonia	B-Pneumococcal_Disease_Type
included	O
in	O
the	O
model	O
;	O
in	O
this	O
scen	O
-	O
ario	O
,	O
the	O
incidence	O
of	O
NTHi	O
ID	O
was	O
assumed	O
to	O
be	O
5	O
%	O
of	O

all	O
Sp	O
IPD	B-Pneumococcal_Disease_Type
cases	O
in	O
children	O
aged	O
<	O
10	O
years	O
,	O
with	O
a	O
CFR	O
of	O
10	O
%	O
.	O

(	O
4	O
)	O
Productivity	O
loss	O
,	O
in	O
which	O
in	O
addition	O
to	O
direct	O
medical	O
costs	O
the	O
model	O
also	O
estimated	O
the	O
time	O
lost	O
from	O
work	O
by	O
patients	O
of	O
working	O
age	O
(	O
18–75	O
years	O
)	O
or	O
time	O
lost	O
from	O
work	O
by	O
parents	O
caring	O
for	O
their	O
sick	O
children	O
.	O

For	O
patients	O
,	O
the	O
time	O
loss	O
estimates	O
were	O
multi	O
-	O
plied	O
by	O
the	O
estimated	O
annual	O
earnings	O
at	O
the	O
indivi	O
-	O
dual’s	O
age	O
,	O
and	O
for	O
working	O
parents	O
(	O
aged	O
18–49	O
years	O
)	O
the	O
time	O
estimates	O
were	O
multiplied	O
by	O
an	O
average	O
annual	O
earnings	O
of	O
£20	O
375	O
(	O
see	O
ﬁ2	O
)	O
.	O
(	O
5	O
)	O
Accounting	O
for	O
the	O
difference	O
in	O
list	O
price	O
of	O
both	O
vaccines	O
in	O
the	O
UK	O
(	O
£49	O
.	O
10	O
/	O
dose	O
and	O
£27	O
.	O
60	O
/	O
dose	O
for	O
PCV	O
-	O
13	O
and	O
PHiD	O
-	O
CV	O
,	O
respectively	O
)	O
.	O

